Which has the lower trailing P/E, ACAD or TMDX?

ACAD has the lower trailing P/E: ACAD trades at 9.06 and TMDX at 21.50. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ACAD or TMDX?

Over the past five years, TMDX grew revenue faster — ACAD at a 19.70% CAGR versus TMDX at 86.12%.

Is ACAD or TMDX more profitable?

ACAD runs the higher net margin — ACAD at 33.42% versus TMDX at 22.69%.

How have ACAD and TMDX total returns compared?

Over the past 5 years, ACAD delivered 3.52% and TMDX delivered 21.77% annualized total return. Past performance doesn't predict future results.

Acadia Pharmaceuticals Inc. (ACAD) vs TransMedics Group, Inc. (TMDX)

A side-by-side comparison of Acadia Pharmaceuticals Inc. and TransMedics Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ACAD

Acadia Pharmaceuticals Inc.

$3.44B

$20.11HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

TMDX

TransMedics Group, Inc.

$2.87B

$82.99HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — ACAD vs TMDX

growth of $100 · dividends reinvested · last 7y

ACAD -15.0% (-2.3%/yr)TMDX +271.2% (+20.6%/yr)TMDX compounded faster over this window

ACAD TMDX

ACAD vs TMDX: by the numbers

•ACAD is the larger company ($3.44B vs $2.87B market cap).
•ACAD trades at the lower trailing earnings multiple (9.06 vs 21.50 P/E), one valuation lens rather than an overall verdict.
•ACAD converts more revenue to profit (33.42% vs 22.69% net margin).
•TMDX grew revenue faster over the past five years (86.12% vs 19.70% CAGR).

Metrics side by side

Valuation

Metric	ACAD	TMDX
P/E ratio	9.06	21.50
Forward P/E	32.65	56.57
P/S ratio	3.02	4.29
P/B ratio	2.64	5.54
EV / EBITDA	31.84	27.65
FCF yield	5.06%	2.76%

Profitability

Metric	ACAD	TMDX
Gross margin	91.13%	58.69%
Operating margin	7.59%	12.21%
Net margin	33.42%	22.69%
ROE	29.12%	29.28%
ROIC	6.25%	5.87%

Growth (annualized)

Metric	ACAD	TMDX
Revenue CAGR (5Y)	19.70%	86.12%
Total return CAGR (5Y)	3.52%	21.77%

Frequently asked

Which has the lower trailing P/E, ACAD or TMDX?: ACAD has the lower trailing P/E: ACAD trades at 9.06 and TMDX at 21.50. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ACAD or TMDX?: Over the past five years, TMDX grew revenue faster — ACAD at a 19.70% CAGR versus TMDX at 86.12%.
Is ACAD or TMDX more profitable?: ACAD runs the higher net margin — ACAD at 33.42% versus TMDX at 22.69%.
How have ACAD and TMDX total returns compared?: Over the past 5 years, ACAD delivered 3.52% and TMDX delivered 21.77% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ACAD analysis Full TMDX analysis Interactive comparison tool

Dig into the metrics

Acadia Pharmaceuticals P/E ratio TransMedics P/E ratio Acadia Pharmaceuticals ROE TransMedics ROE Acadia Pharmaceuticals operating margin TransMedics operating margin Acadia Pharmaceuticals revenue growth TransMedics revenue growth Acadia Pharmaceuticals free cash flow TransMedics free cash flow

Acadia Pharmaceuticals & TransMedics appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest FCF Yield Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.